财务数据显示，截至2024年12月31日，燃石医学收入总额5.16亿人民币，同比减少4.02%；归母净利 润-3.47亿人民币，同比增长46.97%。 大事提醒： 5月27日，燃石医学(BNR)开盘上涨4.54%，截至21:34，报3.398美元/股，成交730.0美元，总市值 3658.06万美元。 燃石医学于2018年7月获国家药品监督管理局(NMPA)颁发的中国肿瘤NGS检测试剂盒第一证,在体外诊 断领域具有里程碑式意义。位于中国广州的实验室通过广东省临床检验中心颁发的"高通量测序实验 室"技术审核,获得美国CLIA和CAP实验室质量体系资质认证;位于美国加利福尼亚州的实验室也已获得 CLIA和CAP实验室质量体系资质认证。公司将继续致力于开发创新可靠的NGS检测产品,推动肿瘤精准 医疗领域的发展。 6月4日，燃石医学将披露2025财年一季报（数据来源于纳斯达克官网，预计披露日期为美国当地时间， 实际披露日期以公司公告为准）。 资料显示，燃石医学有限责任公司成立于2014年,公司使命为"用科学守护生命之光", 专注于为肿瘤精准 医疗提供具有临床价值的二代基因测序(NGS)。公司业务及研发方向主要覆盖:1 ...

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 6.99% on May 20, closing at $2.91 per share, with a total market capitalization of $31.33 million [1] - As of December 31, 2024, the total revenue of Burning Stone Medical is projected to be 516 million RMB, a year-on-year decrease of 4.02%, while the net profit attributable to the parent company is expected to be -347 million RMB, reflecting a year-on-year increase of 46.97% [1] Company Overview - Burning Stone Medical, established in 2014, focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [2] - The company's business and R&D directions include: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [2] - The company received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in July 2018, marking a milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Insights - The stock price of Burning Stone Medical (BNR) increased by 3.31% on May 6, reaching $2.50 per share, with a total market capitalization of $26.9165 million [1] - As of September 30, 2024, the company's total revenue is projected to be 390 million RMB, a year-on-year decrease of 6.38%, while the net profit attributable to the parent company is expected to be -265 million RMB, reflecting a year-on-year increase of 46.01% [1] Company Overview - Burning Stone Medical was established in 2014, with a mission to "guard the light of life with science," focusing on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2] - The company's business and R&D directions primarily cover: 1) tumor patient population testing, holding a leading market share in China; 2) collaborations with global anti-tumor pharmaceutical companies for biomarkers and companion diagnostics; 3) multi-cancer early detection [2] - In July 2018, the company received the first certificate for NGS testing kits for tumors from the National Medical Products Administration (NMPA) in China, marking a milestone in the in vitro diagnostic field [2] - The laboratory located in Guangzhou, China, has passed the technical review by the Guangdong Provincial Clinical Testing Center and obtained quality system certifications from CLIA and CAP; the laboratory in California, USA, has also received CLIA and CAP certifications [2] - The company is committed to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]

Core Viewpoint - The company, Burning Stone Medical (BNR), is experiencing a decline in revenue while showing significant improvement in net profit, indicating a potential shift in operational efficiency and cost management [1][2]. Financial Performance - As of September 30, 2024, Burning Stone Medical reported total revenue of 390 million RMB, a year-over-year decrease of 6.38% [1]. - The company recorded a net profit attributable to shareholders of -265 million RMB, which represents a year-over-year increase of 46.01% [1]. Company Overview - Burning Stone Medical was established in 2014 and focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology [2]. - The company holds a leading market share in tumor patient detection in China and collaborates with global anti-tumor pharmaceutical companies on biomarkers and companion diagnostics [2]. - The company received the first NGS testing kit approval from the National Medical Products Administration (NMPA) in July 2018, marking a significant milestone in the in vitro diagnostic field [2]. - The laboratories in Guangzhou, China, and California, USA, have obtained CLIA and CAP laboratory quality system certifications, ensuring high standards in testing [2].

报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年3月26日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第3号），有 14款产品 进入创新通道。其中包括， 苏州可帮基因科技有限公 司 申请的 结直肠癌数字病理图像微卫星不稳定性分析软件 。 # 研发背景 结直肠癌 （Colorectal Cancer, CRC）是全球范围内最常见的癌症之一。根据GLOBOCAN 2018的数据，结直肠癌是 全球第三 大致死癌症和 第四 大常见癌症。 2018年全球估计有近 200万 新发病例和 约100万 死亡病例。结直肠癌的发病率在全球范围内呈上升趋势，尤其是在发展中国家，这些国家正在逐渐采用"西方"生 活方式，包括高脂肪、高红肉、高酒精摄入以及缺乏运动等。此外，结直肠癌的发病率在不同地区存在显著差异，发达国家的发病率远高于发展中国家。 结直肠癌的疾病负担在全球范围内不断增加。预计到2030年，全球结直肠癌的新发病例数将 增加60% ，达到超过 220万例 ，死亡病例数将达到110万。这种增 长主要归因于经济发展、生活方式的改 ...

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include molecular diagnostic reagents for targeted cancer therapy and chemotherapy, which help clinicians develop personalized treatment plans based on the genetic status of cancer patients [2] Financial Performance - For the third quarter of 2024, the company reported a revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of the latest data, the company's rolling price-to-earnings (PE) ratio is 28.56, while the average PE ratio in the medical device industry is 46.48, and the industry median is 31.96 [1][3] - The total market capitalization of the company is approximately 8.997 billion yuan [1] Institutional Holdings - As of the third quarter of 2024, a total of 264 institutions hold shares in the company, including 263 funds and 1 brokerage, with a total holding of 63.719 million shares valued at 1.453 billion yuan [1]

Company Overview - Xiamen Ade Biological Technology Co., Ltd. specializes in the research, production, and sales of molecular diagnostic products for precision oncology, providing related testing services [2] - The company's main products include targeted drug molecular diagnostic reagents and chemotherapy drug molecular diagnostic reagents, which are used to assess the genetic status of cancer patients [2] - The company holds multiple qualifications, including "National High-tech Enterprise" and "National Enterprise Technology Center," and has received various awards for its research and development efforts [2] Financial Performance - For the third quarter of 2024, the company reported revenue of 848 million yuan, representing a year-on-year increase of 19.84% [3] - The net profit for the same period was 227 million yuan, showing a year-on-year growth of 30.82% [3] - The sales gross margin stood at 84.74% [3] Market Position - As of April 1, the company's stock closed at 23.15 yuan, with a price-to-earnings (PE) ratio of 28.88 times, while the average PE ratio in the medical device industry is 46.46 times [1][3] - The company's total market capitalization is approximately 9.099 billion yuan [1] - In terms of market performance, the company ranked 65th in the industry based on PE ratio [1]